SEC Form 4	
FORM	4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See
Instruction 1(b).

## Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

l	OMB APPROVAL									
I	OMB Number:	3235-0287								

Estimated average burden hours per response: 0.5

1. Name and Address of Reporting Person*			2. Issuer Name and Ticker or Trading Symbol ARS Pharmaceuticals, Inc. [SPRY]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
<u>Tanimoto Sa</u>	arina		[ ~ · · · · ]	Director 🚺 10% Owner					
				Officer (give title Other (specify below)					
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year)	Delow) Delow)					
C/O ARS PHARMACEUTICALS, INC.			10/15/2024	CHIEF MEDICAL OFFICER					
11682 EL CAN	MINO REAL,	SUITE 120							
(Street)			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line)					
SAN DIEGO	СА	92130		Form filed by One Reporting Person					
		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		Form filed by More than One Reporting Person					
(City)	(State)	(Zip)							

## Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Disposed Of	Acquire (D) (Inst	d (A) or r. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
			Code V		Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		(	
Common Stock								3,407,847	D		
Common Stock	10/15/2024		S		48,550 <sup>(1)</sup>	D	\$14.8642 <sup>(2)</sup>	1,398,897	I	By Sarina Tanimoto Charitable Remainde UniTrust Dated January 7, 2020 <sup>(3)</sup>	
Common Stock	10/15/2024		S		1,450(1)	D	\$15.2539 <sup>(4)</sup>	1,397,447	I	By Sarina Tanimoto Charitable Remainder UniTrust Dated January 7, 2020 <sup>(3)</sup>	
Common Stock	10/15/2024		s		50,000 <sup>(1)</sup>	D	\$14.8764 <sup>(5)</sup>	1,298,499	I	By Lowenthal Tanimoto Family Trust U/A DTD 4/3/2006 <sup>(6)</sup>	
Common Stock								1,346,494	I	By Richard E. Lowenthal Charitable Remainder UniTrust Dated January 7, 2020 <sup>(7)</sup>	
Common Stock								4,315,313	I	By Spouse	
Т	able II - Derivativ (e.g., pu	ve Securities / ts, calls, warra						/ Owned		·	

1. Title of Derivative Security <del>(Instr. 3)</del>	2. Conversion or Exercise <del>Price of</del> Derivative Security	3. Transaction <b>Tal</b> Date (Month/Day/Year)	Be IPeeDerivati Execution Date, if any (e.g., pt -(Month/Day/Year)-	1155),d6 (Ahlf	urit Sn, V	iês <sup>N</sup> ACCOU of <b>Britants,</b> Securities Acquired (A) or Disposed of (D)	ifeenterFisco Expiration Da QuestionDay/Q	<del>ରୁହିପଂ</del> ଷ୍ଟ, ( ଜନ୍ମvertib	Amount of Amount of <b>Constitution</b> Underlying Derivative Security (Instr. 3 and 4)	<b>I§ Diwryfe</b> Derivative Security <del>(Instr. 5)</del>	9. Number of derivative Securities <del>Beneficially</del> Owned Following Reported Transaction(s)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial <del>Ownership</del> (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)		4. Transactio Code (ins 8) Code V	on tr.	Hinklimber and 5) Derivative Securities Acquired (A) or Disposed (A) (D) (D)	Expiration Date (Month/Day/Year) Date Exercisable Expiration Date		7. Title and Amount of Securities Underlyingunt Derivative Security (Instr. 5) Security (Instr. 5) Security (Instr. 5) Security (Instr. 5)		f gnatimber of	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Explanatio	n of Respons	es:				(Instr. 3, 4 and 5)					(		

## Explanation of Responses:

L 1. The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023.

The shares were sold pursuant to a rule 1005-1 trading pran entered into on March 31, 2025.
Amount
The weighted average sale price for the transaction reported was \$14.8642 and the range of prices were between \$14.245 and \$15.245 or pron request by the SEC staff, the Issuer, or any security holder
of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
Number
The provided between \$14.245 and \$15.245 or pron request by the SEC staff, the Issuer, or any security holder
Date Expiration of

• Expiration

3. The Reporting Person is trustee of the trust. 4. The weighted average sale price for the transaction reported was \$15.2539 and the range of prices were between \$15.25 and \$15.26. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

5. The weighted average sale price for the transaction reported was \$14.8764, and the range of prices were between \$14.26 and \$15.26. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

6. The shares are held in trust for the benefit of the Reporting Person and her spouse. The Reporting Person and her spouse are trustees of the trust.

7. The Reporting Person's spouse is trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

> /s/ Kathleen Scott, Attorney-10/17/2024 in-Fact

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.